No Data
No Data
Nurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948
Stifel: Maintains Nurix Therapeutics (NRIX.US) rating, adjusted from buy to buy rating, target price $27.00.
Stifel: Maintains Nurix Therapeutics (NRIX.US) rating, adjusted from buy to buy rating, target price $27.00.
Stifel Maintains Buy on Nurix Therapeutics, Maintains $27 Price Target
Stifel analyst Stephen Willey maintains Nurix Therapeutics with a Buy and maintains $27 price target.
Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)